Article thumbnail

Antiviral Activity of 3(2H)- and 6-Chloro-3(2H)-Isoflavenes against Highly Diverged, Neurovirulent Vaccine-Derived, Type2 Poliovirus Sewage Isolates

By Lester M. Shulman, Danit Sofer, Yossi Manor, Ella Mendelson, Jean Balanant, Anna Laura Salvati, Francis Delpeyroux and Lucia Fiore
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). A case for developing antiviral drugs against polio.
  2. (1990). Activities and mechanisms of action of halogen-substituted flavanoids against poliovirus type 2 infection in vitro.
  3. (2007). Advanced environmental surveillance and molecular analyses indicate separate importations rather than endemic circulation of wild type 1 poliovirus in Gaza
  4. (2006). Antiviral activity of substituted homoisoflavonoids on enteroviruses.
  5. (2008). Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range.
  6. (2004). Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia.
  7. (2004). Circulating vaccine-derived polioviruses: current state of knowledge.
  8. (1999). Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority.
  9. (1995). Effect of chloro-, cyano-, and amidino-substituted flavanoids on enterovirus infection in vitro.
  10. (1989). Effect of isoflavans and isoflavenes on the infection of Frp/3 cells by hepatitis A virus.
  11. (2009). Environmental Surveillance for Polioviruses in Israel: Bio-error, Bio-terror or just Mother Nature. In:
  12. (2004). Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man.
  13. (2009). Future of polio vaccines.
  14. (1993). Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates.
  15. (2004). Getting polio eradication back on track in Nigeria.
  16. (2010). Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage.
  17. (2003). Identification of the pocket factors in a picornavirus.
  18. (2008). Immunisation against poliomyelitis: moving forward.
  19. (2010). Implications of a circulating vaccine-derived poliovirus in Nigeria.
  20. (2006). Infectious diseases. Report concludes polio drugs are needed– after disease is eradicated.
  21. (2005). Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient.
  22. (2002). Laboratory Surveillance for Wild Poliovirus and Vaccine -Derived Poliovirus,
  23. (2004). Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus.
  24. (2000). Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel.
  25. (2006). Neurovirulent vaccine-derived polioviruses in sewage from highly immune populations.
  26. (2003). Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis.
  27. (2006). Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
  28. (2001). Picornaviridae: the viruses and their replication.
  29. (2004). Polio eradication in India: some observations.
  30. (2009). Polio eradication. Looking for a little luck.
  31. (2008). Potential use of antiviral agents in polio eradication.
  32. (1972). Problems with oral poliovaccine in India.
  33. (2003). Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future.
  34. (1997). Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes.
  35. (2003). Surge in polio spreads alarm in northern Nigeria. Rumours about vaccine safety in Muslim-run states threaten WHO’s eradication programme.
  36. (2005). Synthesis and anti-rhinovirus properties of fluoro-substituted flavonoids.
  37. (1987). Synthesis and antirhinovirus activity of halogen-substituted isoflavenes and isoflavanes.
  38. (1997). The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.
  39. (2009). Type 2 polio still in our midst.
  40. (2007). Update on vaccine-derived polioviruses–worldwide,
  41. (2005). Vaccine-derived polioviruses and the endgame strategy for global polio eradication.
  42. (1996). WWW-query: an on-line retrieval system for biological sequence banks.